The news you need, when you need it.
This observation should be considered in making clinical decisions regarding patient monitoring when prescribing Hysingla ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong QTc interval.
Gain Essential Business Knowledge. Headquartered in Stamford, CTPurdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. After water interacts with the polymer and diffuses inside it, the outer layer swells due to hydration reaction between water and polyethylene oxide. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, Hysingla ER should be reserved for use in patients for whom alternative treatment options e.
Purdue Pharma's extended-release hydrocodone tablet Hysingla will contain labeling that the drug meets abuse-deterrent properties consistent with the FDA's draft guidance on the topic. Neonatal Opioid Withdrawal Syndrome Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts.
Nevertheless, the abuse-deterrent formulations may become cornerstone opioid treatments in the years to come. The methodology and results of these studies are summarized in section 9. Avoid use in patients with congenital QTc syndrome. A must-read every morning.
Like Zohydro, Hysingla contains an extended-release formula of hydrocodone designed for long-term use. Please anticipate intermittent access to authentication services during this time.
Hysingla ER is not indicated as an as-needed analgesic. However, abuse of Hysingla ER by the intravenous, intranasal, and oral routes is still possible. Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing Hysingla ER, and monitor all patients during therapy for the development of these behaviors or conditions. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products.
Avoid use in patients with congenital QTc syndrome. Our websites may be periodically unavailable between 7 pm CT on Saturday, November 4 and 1 am CT on Sunday, November 5 for regularly scheduled maintenance. Hysingla ER has the following Limitations of Use: Prolonged use of HYSINGLA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts.
News in Focus Browse News Releases. Purchase access Subscribe to Learning for one year. Although the majority of patients take their medications appropriately, an estimated 52 million people have used prescription medications for illicit purposes at least once in their lifetimes.
Hysingla ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Watch here to learn more.
In patients with circulatory shock, Hysingla ER may cause vasodilation that can further reduce cardiac output and blood pressure. Hypotensive Effect Hysingla ER may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients. Addiction can occur at recommended doses and if the drug is misused or abused.